• Home
• Articles
  • Latest Issue
  • Issue Archive
  • Online First
  • Special Issues
• Categories
• HOPA Corner
• Biosimilar Resources
• Web Exclusives
  • All Web Exclusives
  • Did You Know? Beyond the Data
  • Case-Based Exchanges
  • Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
  • Voices From ASCO 2025
  • Conference Correspondent
    • ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
    • ESMO 2025 - Early Breast Cancer
    • ASCO 2025 - Breast Cancer Faculty Commentary
    • ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
  • Interview with the Innovators
  • Rapid Reactions
  • FDA Oncology Update
  • Videos
  • Press Releases
  • Gastrointestinal Cancer Monthly Minutes
  • Quick Quiz
• For Authors
  • Author Guidelines
  • Symptom Management Overview
  • Letters to the Editor/Perspectives
  • Join Our Peer Review
  • Submit a Manuscript
• About
  • About JHOP
  • Contact Us
  • Editorial Policies
  • Peer-Review Process
  • Editorial Board
  • Editorial Process
  • Advertising Policy
  • Advertise

Subscribe

Thmyl Ttbyq Aghany Dydyn Klash Bdwn Nt [better] May 2026

However, the phrase at the end — — is clear.